DRESS Syndrome Induced by Sorafenib in a Patient With Medullary Thyroid Cancer: A Case Report

2020 ◽  
pp. 001857872094676
Author(s):  
Hamid Rahmani ◽  
Niayesh Mohebbi ◽  
Sayed Mahmoud Sajjadi-Jazi
Keyword(s):  
Thyroid Cancer ◽  
Case Report ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Skin Lesions ◽  
Organ Involvement ◽  
Cancer Case ◽  
Dress Syndrome ◽  
Medullary Thyroid ◽  
First Case

Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare and life-threatening hypersensitivity reaction. It is characterized by fever, skin lesions, and internal organ involvement. Sorafenib is a tyrosine kinase inhibitor that is used for the treatment of certain cancers such as hepatocellular, renal cell, and thyroid cancer. Case Presentation: The case is a 40 years old man who presented with fever, generalized skin rash, and pruritus. The patient has received sorafenib for the treatment of medullary thyroid cancer (MTC) from 3 weeks ago. Following presentation, the drug was discontinued and causality was assessed by scoring system RegiSCAR and Naranjo scale that showed a probable DRESS. There was no internal organ involvement based on the laboratory evaluations. The considerable abnormality was eosinophilia among patient’s laboratory tests. Antihistamines and topical and systemic corticosteroids were utilized for the management of the symptoms. Conclusion: To the best of our knowledge, this is the first case report of DRESS syndrome by sorafenib in the patients with MTC. Clinicians should be aware of sign and symptoms suggesting DRESS syndrome of sorafenib.

Neuroendocrine progression of medullary thyroid cancer - case report

2017 ◽  
Author(s):  
Krisztian Sepp ◽  
Zsuzsanna Besenyi ◽  
Laszlo Tiszlavicz ◽  
Zsuzsanna Valkusz
Keyword(s):  
Thyroid Cancer ◽  
Case Report ◽  
Medullary Thyroid Cancer ◽  
Cancer Case ◽  
Medullary Thyroid

Medullary thyroid cancer and pseudocirrhosis: case report and literature review

2012 ◽  
Vol 19 (1) ◽  
Author(s):  
B. L. Harry ◽  
M.L. Smith ◽  
J.R. Burton Jr ◽  
A. Dasari ◽  
S.G. Eckhardt ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Case Report ◽  
Literature Review ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid

scholarly journals The RET Kinase Inhibitor NVP-AST487 Blocks Growth and Calcitonin Gene Expression through Distinct Mechanisms in Medullary Thyroid Cancer Cells

2007 ◽  
Vol 67 (14) ◽  
pp. 6956-6964 ◽  
Author(s):  
Nagako Akeno-Stuart ◽  
Michelle Croyle ◽  
Jeffrey A. Knauf ◽  
Roberta Malaguarnera ◽  
Donata Vitagliano ◽  
...  
Keyword(s):  
Gene Expression ◽  
Thyroid Cancer ◽  
Cancer Cells ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Medullary Thyroid ◽  
Calcitonin Gene ◽  
Thyroid Cancer Cells

Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6074-6074
Author(s):  
Lori J. Wirth ◽  
Eric Jeffrey Sherman ◽  
Daniela Weiler ◽  
Maria E. Cabanillas ◽  
Bruce Robinson ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Systemic Therapy ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Case Reports ◽  
Objective Response ◽  
Previous Response ◽  
Medullary Thyroid ◽  
Prior Therapy ◽  
Altered Thyroid

6074 Background: Selpercatinib is a first-in-class, CNS active, highly selective, and potent RET kinase inhibitor which has demonstrated durable antitumor activity in patients (pts) with RET altered thyroid cancer and is approved in multiple countries for the treatment of RET fusion+ lung or thyroid cancers. As response rates to cancer therapy usually decline on subsequent lines of therapy, the efficacy of selpercatinib was examined in the context of the last prior therapy received before trial enrollment. Methods: Pts with RET mutant medullary thyroid cancer (MTC) previously treated with multikinase inhibitors (cabozantinib and/or vandetanib) were enrolled in the global LIBRETTO-001 trial (NCT03157128). This post-hoc exploratory intrapatient analysis, based on March 30, 2020 data cutoff date, was performed to compare the retrospective physician-reported objective response rate (ORR) from the last systemic therapy prior to enrollment, as reported in pts case reports, to ORR by independent review committee per RECIST 1.1 with selpercatinib treatment, with each patient serving as his/her own control. Results: Efficacy-evaluable pts, 64% male, 90% white with a median age of 58 years, received prior therapy for MTC (n = 143). Pts had a median of 2 (range 1-8) prior systemic regimens. The ORR on selpercatinib (69%) was markedly higher than for the last prior therapy (10%) received before enrollment. ORR improvements with selpercatinib were observed regardless of prior therapy: cabozantinib (66% vs 14%) or vandetanib (71% vs 12%). Fewer pts had progressive disease as their best overall response with selpercatinib (2/143; 1.4%) compared to last prior therapy (33/143; 23.1%). Notably selpercatinib achieved 62% ORR in pts that did not respond to their previous line of therapy prior to enrolment. This shift from non-responder to responder on selpercatinib therapy was consistent regardless of prior cabozantinib or vandetanib treatment, where pts achieved 57% and 61% ORR respectively when subsequently treated with selpercatinib. In contrast, only 3% of patients did not respond to selpercatinib after a previous response to the immediate prior therapy. Similarly, 5% and 2% of patients were non-responders on selpercatinib after a prior response with cabozantinib and vandetanib therapy respectively. Conclusions: Prior to selpercatinib, response with previous multikinase therapy was rare. By contrast, selpercatinib demonstrated robust efficacy regardless of response to or specific prior therapy in pts with RET mutant MTC. Clinical trial information: NCT03157128.

Selpercatinib as an alternative therapy to Lenvatinib for metastatic medullary thyroid cancer. A case report.

2021 ◽  
Author(s):  
Pascual Cristina Contreras ◽  
Mendez Cristina Montalban ◽  
Tirado Antonio Moreno ◽  
Zhao Montero Benítez Maria ◽  
González Lázaro Paloma ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Case Report ◽  
Medullary Thyroid Cancer ◽  
Alternative Therapy ◽  
Medullary Thyroid

Abstract #1003222: Case Report: Medullary Thyroid Cancer as Part of the MEN2B Syndrome in an 8-year-old Male Patient

2021 ◽  
Vol 27 (6) ◽  
pp. S164-S165
Author(s):  
Maria P. Sarmiento ◽  
Judith S. Garcia ◽  
Susana gomez ◽  
Pilar Pereira ◽  
Nora Zuluaga ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Case Report ◽  
Male Patient ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid
Sign in / Sign up

Export Citation Format

Share Document